Lenvatinib suppress FGF19–FGFR4 signaling to enhance antitumor immune response in gastric cancer
Gastric Cancer · 2025
DOI: 10.1007/s10120-025-01596-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, 2025. Verfasst von Yuya Maruyama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, 960-1295, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Phenylurea Compounds, Receptor, Fibroblast Growth Factor, Type 4, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
BACKGROUND: Fibroblast growth factor receptor (FGFR) 4 is overexpressed in gastric cancer (GC) and is a potential therapeutic target for GC. Since the FGF/FGFR signaling is involved in tumor microenvironment inducing the formation of an immunosuppression, lenvatinib is expected to inhibit FGFR4 leading to reduced tumor PD-L1 levels and regulatory T cell (Treg) infiltration, improving pembrolizumab efficacy. This study explored the background of the molecular mechanisms underlying the therapeutic efficacy of lenvatinib plus pembrolizumab. METHODS: Expression of FGFR4 and its specific ligand FGF19 was assessed by immunohistochemical staining and clinicopathological relevance was also examined. The effect of lenvatinib on FGF19-FGFR4 signaling was evaluated using cellular experiments. Lastly, the expression of FGFR4 on Treg cells was evaluated by immunostaining and flow cytometry. The Cancer Genome Atlas cBioPortal and Gene Expression Omnibus microarray databases were accessed to support these results. RESULTS: High FGFR4 expression was associated with histological type and venous invasion and predominantly detected in human epidermal growth factor receptor 2 and Epstein-Barr virus-positive GC. Bioinformatics data suggested that FGF19-FGFR4 signaling was activated in GC, and cellular experiments showed that lenvatinib reduced FGFR4 and PD-L1 expression in GC cells. Results of integrating various analyses suggested that FGFR4 did not seem to be enough expressed on Treg cells in GC. CONCLUSIONS: The FGF19-FGFR4 signaling has a pivotal role in gastric tumorigenesis and may be involved in immunosuppression through PD-L1 modification. But, lenvatinib may not regulate immune editing by directly inhibiting FGFR4 on Treg cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, 960-1295, Japan.
- Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, 960-1295, Japan. moto@fmu.ac.jp.
- Department of Multidisciplinary Treatment of Cancer and Regional Medical Support, Fukushima Medical University School of Medicine, Fukushima, Japan.
- Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan.
- Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan.
ORCID-Profile: Motonobu Saito
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Maruyama, Y., Saito, M., Nakajima, S., Saito, K., Suzuki, H., Kanoda, R., Okayama, H., Hanayama, H., Sakamoto, W., Saze, Z., Momma, T., Mimura, K., Goto, A., & Kono, K. (2025). Lenvatinib suppress FGF19–FGFR4 signaling to enhance antitumor immune response in gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-025-01596-9
Vancouver
Maruyama Y, Saito M, Nakajima S, Saito K, Suzuki H, Kanoda R, et al. Lenvatinib suppress FGF19–FGFR4 signaling to enhance antitumor immune response in gastric cancer. Gastric Cancer. 2025. doi:10.1007/s10120-025-01596-9
BibTeX
@article{Maruyama2025,
author = {Maruyama, Yuya and Saito, Motonobu and Nakajima, Shotaro and Saito, Katsuharu and Suzuki, Hiroya and Kanoda, Ryo and Okayama, Hirokazu and Hanayama, Hiroyuki and Sakamoto, Wataru and Saze, Zenichiro and Momma, Tomoyuki and Mimura, Kosaku and Goto, Akiteru and Kono, Koji},
title = {Lenvatinib suppress FGF19–FGFR4 signaling to enhance antitumor immune response in gastric cancer},
journal = {Gastric Cancer},
year = {2025},
doi = {10.1007/s10120-025-01596-9}
}
EUVIMED